Assessment of adverse event following immunization and its co-relates among COVID-19 vaccine recipient in Bundelkhand region of Uttar Pradesh: A cross-sectional study
DOI:
https://doi.org/10.47203/IJCH.2021.v33i02.027Keywords:
COVID-19, AEFI, Vaccine, Uttar Pradesh, IndiaAbstract
Background: The COVID-19 pandemic is a global emergency. AEFIs reporting and assessment should be done with high priority as they could change the benefit-risk profile of the vaccine. Objective: To assess adverse effects after COVID-19 vaccination. Methods: This cross-sectional study conducted among 605 heath functionaries taken part from January 2021 to March 2021. Results: The most common AEFI reported was pain at injection site (51.9%). Gender, previous COVID status and perception before vaccination were significantly associated with AEFI. Conclusion: There was no serious adverse event after vaccination. COVID vaccine has a good safety profile.
Downloads
References
Coronavirus [Internet]. Who.int. 2021 [cited 30 September 2021]. Available from: https://www.who.int/health-topics/coronavirus#tab=tab_2
[Internet]. Thelancet.com. 2021 [cited 30 October 2021]. Available from: https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(20)30938-7.pdf
Kaushal SK, Kumar N, Yadav M, Patel AK. Modelling of COVID-19 posituve cases at tertiary care hospital of Bundelkhand region of Uttar Pradesh using regression models.Int J Community Med Public Health 2021;8:1899-903.
Lurie N, Saville M, Hatchette, R, &Halton J. Developing Covid-19 vaccines at pandemic speed. The New England Journal of Medicine, 2020,382(21):1969–1973.
https://www.seruminstitute.com/pdf/covishield_fact_sheet.pdf.Last assessed on 25 June 2021.
Ryan MJ, Giles-Vernick T, & Graham JE.. Technologies of trust in epidemic response: openness, reflexivity and accountability during the 2014–2016 Ebola outbreak in West Africa. BMJ Global Health, 2019;4, e001272.
K Park. Park’s Textbook of Preventive and Social Medicine, 25th ed. Jabalpur: Bhanot Publishers; 2019:122-128.
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/en/Factsheetof-ChAdSerum.pdf. Last assessed on 25 June 2021.
Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR. et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomized, controlled, phase 2/3 trial. Lancet. 2021;396(10267):1979-1993.
Schmid, P., Rauber, D., Betsch, C., Lidolt, G., &Denker, M. L. (2017). Barriers of Influenza Vaccination Intention and Behavior - A Systematic Review of Influenza Vaccine Hesitancy, 2005 - 2016. PloS one, 12(1), e0170550. https://doi.org/10.1371/journal.pone.0170550.
Downloads
Published
How to Cite
License
Copyright (c) 2021 Indian Journal of Community Health
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
